Witnessing the stock’s movement on the chart, on Thursday, Becton Dickinson & Co (NYSE: BDX) had a quiet start as it plunged -0.07% to $206.04, before settling in for the price of $206.18 at the close. Taking a more long-term approach, BDX posted a 52-week range of $162.29-$251.99.
The Healthcare sector firm’s twelve-monthly sales growth has been 16.45% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 16.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 3.23%. This publicly-traded company’s shares outstanding now amounts to $285.40 million, simultaneously with a float of $284.52 million. The organization now has a market capitalization sitting at $58.70 billion.
Becton Dickinson & Co (BDX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Medical Instruments & Supplies industry. Becton Dickinson & Co’s current insider ownership accounts for 0.17%, in contrast to 93.85% institutional ownership. According to the most recent insider trade that took place on Jan 15 ’26, this organization’s EVP & Pres Med.Essntl&BioPharm sold 1,610 shares at the rate of 207.46, making the entire transaction reach 334,005 in total value, affecting insider ownership by 12,095.
Becton Dickinson & Co (BDX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.33 per share during the current fiscal year.
Becton Dickinson & Co’s EPS increase for this current 12-month fiscal period is 3.23% and is forecasted to reach 15.78 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 4.39% through the next 5 years, which can be compared against the 16.45% growth it accomplished over the previous five years trading on the market.
Becton Dickinson & Co (NYSE: BDX) Trading Performance Indicators
Let’s observe the current performance indicators for Becton Dickinson & Co (BDX). It’s Quick Ratio in the last reported quarter now stands at 0.64. Alongside those numbers, its PE Ratio stands at $35.34, and its Beta score is 0.25. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.69. Similarly, its price to free cash flow for trailing twelve months is now 21.99.
In the same vein, BDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 5.83, a figure that is expected to reach 2.81 in the next quarter, and analysts are predicting that it will be 15.78 at the market close of one year from today.
